MannKind News

Analysts Offer Insights on Healthcare Companies: MannKind (MNKD), Vertex Pharmaceuticals (VRTX) and Korro Bio (KRRO)

TipRanksApr 8 22:30 ET

MannKind Analyst Ratings

BenzingaMar 15 10:50 ET

MannKind's Strong Q4 Financials and Therapeutic Portfolio Potential Merit a Buy Rating

TipRanksMar 1 01:06 ET

MannKind Corporation: Strong Growth and Clinical Advancements Prompt Buy Rating

TipRanksFeb 28 08:55 ET

MannKind (MNKD) Receives a New Rating From Cantor Fitzgerald

TipRanksFeb 28 08:35 ET

RBC Capital Sticks to Their Hold Rating for MannKind (MNKD)

TipRanksFeb 28 07:19 ET

MannKind (MNKD) Receives a Hold From RBC Capital

TipRanksJan 5 20:47 ET

Strategic Deal Boosts MannKind's Financial Prospects: A Buy Rating Justified

TipRanksJan 4 23:56 ET

HC Wainwright & Co. Reiterates Buy on MannKind, Maintains $7.5 Price Target

BenzingaJan 4 06:29 ET

MannKind Analyst Ratings

BenzingaJan 4 06:28 ET

MannKind Buy Rating Affirmed: Financial Strength and Market Potential Underpin Positive Outlook

TipRanksJan 4 06:16 ET

Oppenheimer Reaffirms Their Buy Rating on MannKind (MNKD)

TipRanksDec 21, 2023 07:35 ET

Oppenheimer Adjusts MannKind Price Target to $5.50 From $6.50, Maintains Outperform Rating

MT NewswiresNov 14, 2023 08:21 ET

Strong Q3 Results and Promising Clinical Progress: A Buy Rating for MannKind

TipRanksNov 10, 2023 06:31 ET

Promising Growth and Expansion Potential Elevates MannKind to a Buy Rating

TipRanksNov 8, 2023 22:36 ET

RBC Capital Sticks to Their Hold Rating for MannKind (MNKD)

TipRanksNov 8, 2023 20:48 ET

Analysts' Top Healthcare Picks: MannKind (MNKD), Stoke Therapeutics (STOK)

TipRanksNov 8, 2023 06:30 ET

Wedbush Initiates Coverage On MannKind With Outperform Rating, Announces Price Target of $10

BenzingaOct 10, 2023 05:13 ET

MannKind Analyst Ratings

BenzingaOct 10, 2023 05:12 ET

RBC Capital Remains a Hold on MannKind (MNKD)

TipRanksOct 5, 2023 21:49 ET